Skip to main content

AS/Spondyloarthritis

RheumNow Podcast square

What Worries You, Masters You (7.1.2022)

Jul 01, 2022

Dr. Jack Cush reviews recent news, regulatory and guideline updates from the past week on RheumNow.com.  Studies on methotrexate use, COVID vaccination, Supplements and vitamins, and arthrocentesis despite anticoagulation are discussed.




  1. FDA approved Abbvies risakizumab-rzaa

Read Article
psA.fil_.toes_.jpg

Inferior IL-17 Inhibitor Responses in Psoriatic Women

Jun 27, 2022

Pooled data from two large ixekizumab (IXE) trials show that male patients had greater clinical responses than did female patients with psoriatic arthritis are largely unexplored. Reasons for this differential treatment responses to an interleukin-17A inhibitor (IXE) between male and female

Read Article
virus,injection,COVID,vaccine

Two Week Methotrexate Hold with COVID-19 Vaccination

Jun 24, 2022

A cohort study of rheumatoid arthritis (RA) patients evaluated immunogenicity of COVID vaccination with and without holding methotrexate (MTX) for and 2-weeks and showed better immunogenicity, but more RA flares with the second MTX withdrawal. 

Read Article
#EULAR2022 has concluded but you can find all our coverage here https://t.co/s62OVJPQ86 https://t.co/QAvPQYCABj
Dr. John Cush @RheumNow( View Tweet )
Jun 18, 2022
RheumNow Podcast square

Two Week Twitter (6.17.2022)

Jun 17, 2022

Dr. Jack Cush does a 2-week review of RheumNow Tweets on news and journal citations worth noting, along with some opinions on Telehealth, manpower, monkeypox and the price of drugs.




  1. Although Rheumatology currently ranks 2nd or 3rd in specialty use of telemedicine - the vast

Read Article
covid coronavirus virus

Spondyloarthritis and COVID-19

Jun 15, 2022

There are still questions surrounding COVID-19, and some common questions I receive from patients revolve around what to do with their current DMARDs or should they even start treatment during this pandemic. Two studies focused on this question. 

Read Article
450 axSpA pts followed 2868 Pt-yrs, 48% on TNFis. TNFi Rx pts had reduced CV risk (HR 0.30; 0.10–0.85), but no longer signif after adjustment for CRP, ESR (HR 0.37, 0.12–1.12, p = 0.077). Reduced CV risk, may not be specifically due to TNFi use https://t.co/mVHYn3PteL https://t.co/bgKWreBL8z
Dr. John Cush @RheumNow( View Tweet )
Jun 14, 2022
Watch: The Microbiome in Spondyloarthritis Can microbes trigger SpA/PsA?https://t.co/KN7dMFU9qo https://t.co/k3M5QfwqGp
Dr. John Cush @RheumNow( View Tweet )
Jun 14, 2022
RheumNow Podcast square

EULAR 2022 Top 10 Abstracts (6.10.2022)

Jun 10, 2022

Dr. Jack Cush reviews the top abstracts from EULAR 2022  As chosen by me with the  aid of the RheumNow EULAR faculty. “Top” is relative and subjective, but my criteria for inclusion are based on impact, water cooler talk potential, innovation and social media buzz.  Speaking of social media

Read Article
Watch: Let’s Talk about Sex and Autoimmune Disease Dr. Eric Dein discusses abstract OP0139 presented at #EULAR2022. https://t.co/fNcIbykFqL https://t.co/6UaH5DIc51
Dr. John Cush @RheumNow( View Tweet )
Jun 07, 2022
Gender

Time to consider gender stratification in AxSpA diagnosis and management

Differences across genders in many aspects related to rheumatic diseases diagnosis, phenotyping, trajectories definition and prediction of response to treatment have been overlooked. Two abstracts have shed light on relevant gender-based differences in AxSpA assessment or treatment.

Read Article
Updates on Axial SpA from #EULAR2022 @RheumNow https://t.co/0dGPUpksxT

Dr. Antoni Chan @synovialjoints( View Tweet )

Jun 05, 2022
Update on Axial SpA at #EULAR2022 This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). Dr Antoni Chan shares his picks of abstracts from the conference.https://t.co/AhUC7ORrZi https://t.co/1olLoNS5Ey
Dr. John Cush @RheumNow( View Tweet )
Jun 05, 2022
Spondyloarthritis and COVID-19 With the availability of vaccines and new therapeutics, many of our patients are fully vaccinated. We know this can limit their chances of severe COVID all while allowing their rheumatic disease to be treated. #EULAR2022 https://t.co/PmQNKYg1Ao https://t.co/N4DJVYJqrL
Dr. John Cush @RheumNow( View Tweet )
Jun 05, 2022
Axial Spondyloarthritis

Update on Axial SpA at EULAR 2022

Jun 04, 2022

This year at EULAR 2022, there were important and interesting topics in Axial Spondyloarthritis (AxSpA). These are my picks of abstracts from the conference.

Read Article
New biomarker for atherosclerosis, cardiovascular risk and disease activity in axSpA? Low Irisin associated with subclinical atherosclerosis, high CV risk and more severe disease activity in axSpA @RheumNow #EULAR2022 ABST#POS0327

Robert B Chao, MD @doctorRBC( View Tweet )

Jun 04, 2022
Sex differences in axSpA: we’re continuing to better understand the differences in imaging findings. Existing MRI scoring may underserve axSpA in women. Added to therapy differences, a lot to readdress for our female axSpA patients. from roundup #EULAR2022 @RheumNow https://t.co/8wCKx9AFcM
Jun 04, 2022
Gut microbiome of AS patients different from healthy controls. Different bacteria communities may be associated with disease activity. So much more to digest.... @RheumNow #EULAR2022 ABST#POS0330 https://t.co/EAvHngd6SD
Robert B Chao, MD @doctorRBC( View Tweet )
Jun 04, 2022
Tofacitinib had faster and larger impact on improvement of fatigue compared to placebo in treatment of ankylosing spondylitis pts. Note 100% fatigue resolution roughly same vs. placebo @RheumNow #EULAR2022 ABST#POS0305 https://t.co/Doep91QIRa
Robert B Chao, MD @doctorRBC( View Tweet )
Jun 04, 2022
Upadacitinib effective in treatment of ankylosing spondylitis pts refractory to biologic tx - phase 3 trial Primary endpoint (ASAS40) and secondary endpoints met No malignancy, MACE, VTE, death @RheumNow #EULAR2022 ABST#POS0306 https://t.co/UL4hUJ0rQV
Robert B Chao, MD @doctorRBC( View Tweet )
Jun 04, 2022
Does treating spondyloarthritis early matter? Systematic review showed in nr-axSpA tx with biologics may lead to better outcomes compared to established axSpA axSpA - no difference in response between early vs. established disease @RheumNow #EULAR2022 ABST#POS0302

Robert B Chao, MD @doctorRBC( View Tweet )

Jun 04, 2022
What guides treatment decisions in AxSpA? Bolt et al showed patients assessed in clinical remission, 1/3 had BASDAI >3.5. Treatment unchanged as low disease activity, awaiting effects of current Rx, complaints not related to axSpA, patient preference #EULAR2022 @RheumNow POS0303

Dr. Antoni Chan @synovialjoints( View Tweet )

Jun 04, 2022
Treatment of active SpA improves depressive symptoms in SpA with HADS-D score reducing. This was greatest for TNFi followed by NSAIDs and csDMARDs. TNFi reduced the proportion of patients (48% to 29%) with depressive symptoms at follow up Webers et al #EULAR2022 @RheumNow POS0304

Dr. Antoni Chan @synovialjoints( View Tweet )

Jun 04, 2022
Wetterslev et al showed that almost all of 108 axSpA patients in clinical remission flared during tapering,47% flared at 2/3 to ½ dose and 53% at 1/3 to discontinuation. Higher baseline physician global score was an independent predictor of flare #EULAR2022 @RheumNow POS0298 https://t.co/RELuiB3Enl
Dr. Antoni Chan @synovialjoints( View Tweet )
Jun 04, 2022
New in AS. Upadacitinib 15mg od was significantly more effective than placebo over 14 weeks in AS bDMARD-IR (ASAS40 45% vs 18% and the onset of effect seen by week 4), no new safety risks identified in the SELECT-AXIS 2 study by Van de Heijde et al #EULAR2022 @RheumNow POS0306 https://t.co/LCQBf38GWe
Dr. Antoni Chan @synovialjoints( View Tweet )
Jun 04, 2022
×